MUC16 and ovarian carcinoma: In conclusion, while the specificity of calprotectin is considered inferior to CA-125—given that many women with BOTs present with plasma calprotectin concentrations above clinically relevant thresholds—its elevated levels in ovarian carcinoma could indicate advanced stages of the carcinogenesis pathway.